Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

BACKGROUND: Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib. Experimental evid...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosell, Rafael, Perez-Roca, Laia, Sanchez, Jose Javier, Cobo, Manuel, Moran, Teresa, Chaib, Imane, Provencio, Mariano, Domine, Manuel, Sala, Maria Angeles, Jimenez, Ulpiano, Diz, Pilar, Barneto, Isidoro, Macias, Jose Antonio, de las Peñas, Ramon, Catot, Silvia, Isla, Dolores, Sanchez, Jose Miguel, Ibeas, Rafael, Lopez-Vivanco, Guillermo, Oramas, Juana, Mendez, Pedro, Reguart, Noemi, Blanco, Remei, Taron, Miquel
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673583/
https://www.ncbi.nlm.nih.gov/pubmed/19415121
http://dx.doi.org/10.1371/journal.pone.0005133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673583/
https://www.ncbi.nlm.nih.gov/pubmed/19415121
http://dx.doi.org/10.1371/journal.pone.0005133

Ejemplares similares